|Circadian Technologies Limited|
650 Chapel Street
Australia - Map
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
Circadian Technologies Limited develops and commercializes therapies for eye and cancer diseases in Australia. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets, which are used for the treatment of diseases associated with angiogenesis. The companys lead molecule includes OPT-302, a soluble form of VEGFR-3 that is used for the treatment of neovascular age-related macular degeneration and dry-eye diseases. Its product pipeline also comprises VGX-100, a monoclonal antibody for VEGF-C that has completed Phase IA/IB clinical study in advanced cancer patients; and IMC-3C5, an antibody targeting VEGFR-3. In addition, the company develops CUPGUIDE, a diagnostic test, which is used in the treatment of cancers of unknown primary; and VEGF-D LAM Diagnostic, an ELISA-based diagnostic test to measure circulating levels of VEGF-D, as well as offers VEGF-C/VEGF-D reagents under the Vegenics brand name. Further, it develops novel forms of insulin through DiMiTech Platform that is used for the treatment of diabetes. Circadian Technologies Limited is based in South Yarra, Australia.
|Ms. Dominique Gayle Fisher BA (Hons), MAICD,
Chairman, Chairman of Remuneration Committee and Member of Audit & Risk Committee
|Ms. Megan Baldwin Ph.D.,
Chief Exec. Officer, Managing Director and Director
|Mr. Michael Tonroe ,
Chief Financial Officer and Company Sec.
|Mr. Richard Chadwick Ph.D.,
Head of Intellectual Property
|Mr. Michael Gerometta Ph.D.,
Head of CMC Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|